Search - tctmd.com

Displaying 1 - 20 of 174

Sort: Relevancy | Date

News Daily News

FAME 2 at 10 Years: Less Urgent Revascularization With FFR-Guided PCI

Michael O'Riordan

January 26, 2026

News Daily News

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

Yael L. Maxwell

December 29, 2025

Presentation TCT 2025

TCT 216: Outcomes based on the completeness of revascularization in patients with three-vessel coronary artery disease: The FAME 3 Trial

Presenter: Hisao Otsuki

October 26, 2025

Presentation TCT 2025

Recent Coronary Trials: Role of Physiology - Put the Brakes On! (FAME 3; FAVOR 3; FLOWER MI)

Presenter: Kyung Woo Park

October 26, 2025

Presentation TCT 2025

Cost-Effectiveness of CABG vs. PCI for Multivessel Disease: The FAME 3 Trial

Presenter: Mark Andrew Hlatky

October 25, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2025

Caitlin E. Cox

April 30, 2025

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Caitlin E. Cox

March 31, 2025

Presentation ACC 2025

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

Presenter: William Fearon

March 30, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2024

Caitlin E. Cox

December 31, 2024

News Daily News

Potential Sex Differences Seen for FFR-Guided PCI vs CABG in FAME 3

Todd Neale

December 09, 2024

Presentation TCT 2024

TCT 23: Outcomes After FFR-Guided PCI Compared With CABG in Patients Presenting With Acute Coronary Syndrome: A Pre-Specified Subgroup Analysis of the FAME 3 Trial

Presenter: Kuniaki Takahashi

October 28, 2024

News Conference News EuroPCR 2024

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

Yael L. Maxwell

May 17, 2024

News Daily News

PCI With Intravascular Imaging or Functional Testing Bests Angiography Alone

Michael O'Riordan

November 24, 2023

Presentation TCT 2023

TCT 340: Sex Differences in Patients with Three-vessel Coronary Artery Disease Undergoing FFR-guided PCI or CABG: A Pre-specified Analysis of the FAME 3 Trial

Presenter: Kuniaki Takahashi

October 26, 2023

Presentation TCT 2023

TCT 142: Impact of Chronic Total Occlusions on Outcomes in The FAME 3 Trial

Presenter: Hisao Otsuki

October 24, 2023

News Daily News

Sham Procedures in CV Research: What’s Sacrificed for Science?

Caitlin E. Cox

October 23, 2023

News Daily News

‘Functional’ SYNTAX Score May Hone PCI, CABG Choices in Multivessel Disease

Michael O'Riordan

September 13, 2023

News Conference News EuroPCR 2023

Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization

Michael O'Riordan

May 19, 2023

News Opinion Off Script

As We Flock to AI, Let’s Not Forget the EQ

Nicole Bart, MD, PhD

May 04, 2023

Advertisement

FAME 2 at 10 Years: Less Urgent Revascularization With FFR-Guided PCI

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

TCT 216: Outcomes based on the completeness of revascularization in patients with three-vessel coronary artery disease: The FAME 3 Trial

Recent Coronary Trials: Role of Physiology - Put the Brakes On! (FAME 3; FAVOR 3; FLOWER MI)

Cost-Effectiveness of CABG vs. PCI for Multivessel Disease: The FAME 3 Trial

TCTMD’s Top 10 Most Popular Stories for April 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

What’s Going to Be Hot at ACC 2025?

TCTMD’s Top 10 Most Popular Stories for December 2024

Potential Sex Differences Seen for FFR-Guided PCI vs CABG in FAME 3

TCT 23: Outcomes After FFR-Guided PCI Compared With CABG in Patients Presenting With Acute Coronary Syndrome: A Pre-Specified Subgroup Analysis of the FAME 3 Trial

PCI for Multivessel Disease More Cost-effective Than CABG at 3 Years: FAME 3

PCI With Intravascular Imaging or Functional Testing Bests Angiography Alone

TCT 340: Sex Differences in Patients with Three-vessel Coronary Artery Disease Undergoing FFR-guided PCI or CABG: A Pre-specified Analysis of the FAME 3 Trial

TCT 142: Impact of Chronic Total Occlusions on Outcomes in The FAME 3 Trial

Sham Procedures in CV Research: What’s Sacrificed for Science?

‘Functional’ SYNTAX Score May Hone PCI, CABG Choices in Multivessel Disease

Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization

As We Flock to AI, Let’s Not Forget the EQ

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content